In August 2025, prices for ketoprofen, a key non-steroidal anti-inflammatory drug (NSAID), experienced a notable rebound following a period of decline. The price stabilization is attributed to increased domestic demand in China, regulatory shifts, and supply chain stabilization. As the largest producer and exporter of ketoprofen, China's market dynamics significantly influence global pricing, particularly for major importers like the USA and Germany.
Key Highlights
-
A seasonal uptick in demand for ketoprofen is observed as consumers seek pain relief medications.
-
Recent clarifications in China&#xx;s pharmaceutical regulations have fostered a stable production environment.
-
Improved logistics and distribution networks have enhanced access to ketoprofen.
-
Growing demand in Southeast Asian markets is prompting increased production and export of ketoprofen.
Chinese consumption of ketoprofen has registered an unprecedented increase, especially in the pharmaceutical industry, as a result of health-related seasonal variations. With the change from summer to fall, cases of ailments that necessitate pain relief, like arthritis and post-surgery convalescence, have been on the rise. Off-the-counter sales of ketoprofen have been supported by increased consumer knowledge as well as access to the drug. The effect of Indian bans on veterinary drugs has also altered some patterns of demand, limiting competition and creating a more stable price environment for the setting of ketoprofen use in human...
